Marshall Urist, M.D., Ph.D., is a distinguished figure in the field of biomedical research and investment, currently serving as the Executive Vice President of Research & Investments at Royalty Pharma PLC Class A. Dr. Urist's academic journey is marked by his attainment of both a medical degree (M.D.) and a doctorate in philosophy (Ph.D.), showcasing his deep commitment to advancing medical science. His expertise spans multiple disciplines, including molecular biology, pharmacology, and healthcare economics, which he leverages to drive strategic investment decisions at Royalty Pharma. In his role at Royalty Pharma, Dr. Urist plays a pivotal part in identifying and capitalizing on high-potential biomedical innovations. His responsibilities include overseeing the company's research initiatives and investment portfolio, ensuring that Royalty Pharma remains at the forefront of the pharmaceutical industry. Under his guidance, the company has successfully invested in numerous groundbreaking therapies and treatments, significantly enhancing its market position and contributing to global health advancements. Dr. Urist's strategic vision and scientific acumen have been instrumental in fostering collaborations with leading research institutions and biotech firms, further solidifying Royalty Pharma's reputation as a key player in the industry. Dr. Urist's professional achievements extend beyond his current position. He has authored numerous peer-reviewed articles and has been a sought-after speaker at international conferences, sharing insights on the intersection of medical research and investment strategy. His contributions to the field have earned him recognition and respect from peers and industry leaders alike. Dr. Urist's dedication to improving patient outcomes through innovative investment strategies continues to drive Royalty Pharma's mission to transform the landscape of healthcare financing and delivery.